Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.30 |
| ▸ | ACP1 | P24666 | 2/20 | 0.30 |
| ▸ | CDC25B | P30305 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960830 | 0.85 | POLB (0.33) | POLBTSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL15960848 | 0.71 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2 | |
| SCHEMBL15960847 | 0.71 | TSHR (0.36) | POLBTSHRL3MBTL1SMN1; SMN2PTPN1 | |
| SCHEMBL21999082 | 0.66 | GLA (0.43) | TSHRSMN1; SMN2PTPN1ACP1CDC25B | |
| SCHEMBL1562353 | 0.65 | TSHR (0.38) | POLBTSHRL3MBTL1SMN1; SMN2PTPN1 | |
| SCHEMBL9669122 | 0.64 | POLB (0.35) | POLBTSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL30791475 | 0.63 | PTPN1 (0.35) | PTPN1ACP1CDC25B | |
| SCHEMBL11865670 | 0.63 | — | — | |
| SCHEMBL18828627 | 0.62 | — | — | |
| SCHEMBL11865829 | 0.62 | CYP1A2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020052545-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATES THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| WO-2020051796-A1 | PREPARATION METHOD FOR BRIVARACETAM AND INTERMEDIATE THEREOF | 上海宣泰医药科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| WO-2010111622-A2 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111622-A2 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| EP-1993998-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007065634-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065634-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | ANPEP, DNPEP, NAAA | POLB 1507/4885TSHR 1653/4885L3MBTL1 1006/4885 |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | ALDH18A1, PYCR1, OPRD1 | POLB 620/4885TSHR 4398/4885L3MBTL1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.